NDATOPICALGEL
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
CABTREO (clindamycin phosphate/benzoyl peroxide/adapalene) by Bausch + Lomb. Approved for retinoid [epc]. First approved in 2023.
Drug data last refreshed 7h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CABTREO is a fixed-dose topical gel combining clindamycin phosphate (antibiotic), benzoyl peroxide (antimicrobial), and adapalene (retinoid) approved in October 2023 for acne treatment. The triple-action formulation targets acne through bacterial suppression, comedone extrusion, and normalized follicular epithelial cell turnover. This novel combination represents an advance over dual-agent formulations in the retinoid acne market.
Growth14.3 years to LOE
Early-stage growth product with zero reported competitive pressure, creating opportunity for field teams to establish market share and build category awareness.
Mechanism of Action
Pharmacologic Class:
Retinoid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo
Started Apr 2026
100 enrolled
Acne Vulgaris
Career Relevance
CABTREO represents a rare opportunity to launch a novel fixed-dose combination in a high-volume dermatology market with minimal direct competition and strong patent protection through 2040. Joining the commercial team now positions you to build market infrastructure, establish formulary relationships, and capture share before generic competition accelerates in 2029.
Brand Manager
Worked on CABTREO at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.